BioLoomics is at the forefront of developing advanced antibody-drug conjugates (ADCs) aimed at enhancing cancer therapies. The company employs directed evolution techniques to improve the internalization and trafficking of these ADCs, specifically targeting peptide-antibody chimeras to precise subcellular organelles. This innovative approach is designed to overcome the limitations of traditional ADCs, such as poor tumor uptake, thereby increasing both safety and efficacy in cancer treatment. BioLoomics' technology integrates synthetic biology, artificial intelligence, imaging, and robotics to create a robust pipeline of anti-cancer therapies, focusing on lysosomal targeting to enhance drug delivery mechanisms.

In addition to its work on ADCs, BioLoomics is pioneering a biosensing drug discovery platform that utilizes single live cells for high-throughput screening. This platform aims to improve the clinical success rate of drug development by generating extensive libraries of biosensor assays with pathway specificity and high dynamic range. The company’s interdisciplinary team combines expertise in synthetic biology, machine learning, and protein design to address unmet medical needs in oncology. With significant funding and a commitment to innovation, BioLoomics is positioned to make substantial contributions to the field of cancer therapeutics.

United States

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML. 

BioLoomics

Company Details